Chronic Kidney Disease. Done Right.

Chronic Kidney Disease. Done Right.

Renin-aldosterone system inhibitors are the mainstay of therapy for preventing and slowing the progression of chronic kidney disease. Novel therapies have been investigated for their ability to further limit disease progression. Join us to learn if allopurinol is a worthwhile add-on therapy for chronic kidney disease.

Upon successful completion of this application-based course, pharmacists and pharmacy students should be able to:
1. Discuss the pathophysiology of chronic kidney disease
2. Describe current guideline-endorsed management strategies for chronic kidney disease
3. Recognize the results of a randomized control trial evaluating allopurinol to treat stage 3-4 chronic kidney disease
4. Review strengths and limitations in the design of a randomized trial evaluating allopurinol to treat stage 3-4 chronic kidney disease
5. Develop a conclusion for the clinical appropriateness of care based on a clinical trial

Joseph Berendse
Assistant Professor
South Dakota State University

Joseph Berendse does not report any actual or potential conflicts of interest in relation to this continuing pharmacy education course. 

CEimpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read:

Badve S, Pascoe E, Tiku A, et al. Effects of Allopurinol on the Progression of Chronic Kidney Disease. New England Journal of Medicine. ; 382:2504-2513
DOI: 10.1056/NEJMoa1915833.
Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa1915833

The article this month is from The New England Journal of Medicine and may be behind a paywall. We encourage preceptors to take advantage of journal access through university affiliation. Additionally, a free account to NEJM.org provides access to 2 subscriber-only articles per month, if access through a university is not possible. If you have any questions, please contact us at team@ceimpact.com.  

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

This course is included in our Pharmacist Subscription Services. To get more courses like this sent to you every month, sign-up for a CE Subscription Service!

Fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: February 10, 2021
Planned Expiration Date: February 10, 2024  

RV3-10.23/EXP

Universal Activity Number (UAN): 0107-0000-21-009-H01-P
Application-based CPE Activity

CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at www.MyCPEMonitor.net.

¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.

Additional information

Duration

1h 0m

Topic Designator

Disease State/Drug Therapy

ACPE

Yes

ACPE Topic

01 Drug Therapy

Role

Pharmacist

Media-Type

On-Demand

Release Date

2/10/21

CEUs

0.1

Rating

4

ACPE Number

0107-0000-21-009-H01-P

This course is in our subscription.

0